DSM-Firmenich: A Genuine Portfolio Cleanup, Already Priced for the Improvement to Continue

The right label is a company in transition, not a high-quality compounding growth name yet and not a cyclical-reversal case either. The portfolio has improved faster than the market narrative had expected a year ago. The operating model is cleaner. Fine fragrance is stronger than skeptics gave it credit for. Capital allocation has become more disciplined. But the transition is not finished, because HNC still needs more consistent delivery, the ANH sale is not yet a closed and fully monetized fact in the evidence reviewed here, and formal segment reporting still shows a more complex business than the simplified equity story. That combination justifies a balanced stance: this is a better business than the old bear case assumed, but the current price already reflects a fair amount of that improvement.

Company history and financial review

dsm-firmenich’s history works only if it is treated as two separate lineages that met late in life. Firmenich began in Geneva in 1895 when Philippe Chuit and Martin Naef built a perfume-and-aroma business around molecule creation, customer intimacy and long-cycle creative relationships. DSM began in the Netherlands in 1902 as Dutch State Mines, became a chemicals company after mining faded, listed in Amsterdam in 1989, and then spent decades remaking itself through divestitures and acquisitions into nutrition, health and bioscience. By the time DSM and Firmenich agreed their “merger of equals” in 2022 and completed it in May 2023, each side had already done the hard identity shift: Firmenich had outgrown the image of a family house without public-market discipline, and DSM had largely abandoned the image of a diversified materials group in favor of higher-value nutrition and health.

The deal logic was easy to explain and much harder to deliver. At announcement, DSM shareholders were to own 65.5% of the new company and Firmenich shareholders 34.5%, with Thomas Leysen designated chairman and Patrick Firmenich vice-chair. The boards sold the combination as the leading creation-and-innovation partner in nutrition, beauty and well-being: DSM would bring health, nutrition and bioscience capabilities; Firmenich would bring taste, perfumery, captive ingredients and a stronger luxury/consumer pull. The promised result was a group large enough to sit beside Givaudan, IFF and Symrise, but with a broader “nutrition plus beauty” angle than any one of them.

The first stage after closing was not glamorous. 2023 and early 2024 were spent proving that the combined group could function, not proving that it was special. ANH was the spoiler. Vitamins weakened sharply, animal-protein and feed markets remained messy, and the lower-quality parts of the old DSM portfolio kept bleeding into the group’s valuation. Public investors therefore did what they usually do when a merger arrives with too many moving parts: they paid for the best business only after discounting the rest. That set up the second act. In 2024 and 2025, management completed a strategic business and portfolio review, exited Feed Enzymes in June 2025 for €1.5 billion, accelerated the €1.08 billion buyback funded by that exit, and made ANH separation the crucial unfinished task.

The February 2026 ANH agreement with CVC was therefore more than another transaction. It was the moment management chose shape over nostalgia. The business will be split into standalone Swiss companies, dsm-firmenich will retain a 20% equity stake in both, the company will receive an estimated €1.2 billion of value at closing composed of about €0.6 billion net cash, about €0.5 billion of debt and liability transfer, and a €0.1 billion vendor loan note, and it will also provide a loan facility of up to €450 million plus possible additional liquidity support of up to €115 million if needed. Strategically that finishes the consumer pivot. Financially it is less clean than a full-cash exit, which is why some investors liked the direction but disliked the price.

A vertical reading of the financials shows a company getting better, but not yet settled. On a continuing-operations basis, 2025 sales were €9.034 billion and adjusted EBITDA €1.772 billion, for a 19.6% margin. Core adjusted EBIT rose to €1.290 billion, core adjusted ROCE improved to 11.1%, and adjusted gross operating free cash flow reached €950 million, equivalent to 10.5% cash conversion. Net debt was €3.301 billion at year-end 2025. The shape inside those totals matters more than the totals themselves: Perfumery & Beauty generated €3.760 billion of sales at a 21.7% adjusted EBITDA margin; Taste, Texture & Health generated €3.146 billion at 20.6%; Health, Nutrition & Care generated €2.102 billion at 19.4%. That margin spread tells the story of the business more clearly than any mission statement: the company’s best economics still sit closer to fragrance and premium formulation than to volumetric nutrition.

Cash quality, within the limits of the short post-merger record, is better than many transition stories. Adjusted gross operating free cash flow exceeded core adjusted net profit in both 2024 and 2025, with the 2025 AGOFCF/core adjusted net profit ratio at roughly 1.07x and the 2024 ratio around 1.25x. Working capital remains heavy at 28.8% of sales, which is one reason management’s 2026–2027 action plan puts so much emphasis on working-capital tightening and normalized capital expenditure. Still, this is decent, cash-backed conversion that should improve further if the portfolio simplification works.

The capital-market history since listing as dsm-firmenich is short but revealing. The market rewarded the company in February 2025 when annual results slightly beat expectations and management paired them with a new buyback and higher 2025 profit expectations; Reuters reported the shares rose as much as 7.7% intraday and were still up 3.5% by late morning. In February 2026, the ANH sale announcement disappointed some investors because the headline value looked softer than hoped. In May 2026, the Q1 trading update reversed that tone: volume-led growth, especially in fine fragrance, pushed the shares up more than 6% in early trading. The stock the market is willing to own at €85 is therefore one that has moved from “prove the merger” to “prove the cleaner portfolio can earn a better multiple.”

Business model and industry

The commercial engine is built on formulation intimacy, not commodity throughput. Perfumery & Beauty sells creative solutions and captive ingredients into fine fragrance, consumer fragrances, and beauty-and-care applications. Taste, Texture & Health sells flavors, extracts, sweetening systems, enzymes, hydrocolloids, cultures, natural colors, plant proteins and related nutritional ingredients into food and beverages. Health, Nutrition & Care sells early-life nutrition ingredients, biomedical solutions, dietary supplements and pharma-adjacent offerings. That spread can look messy at first glance, but there is a common economic grammar underneath it: regulatory know-how, application expertise, customer co-development, long qualification cycles and a portfolio of ingredients that customers often embed into products where reformulation is costly and commercially risky.

The cost structure is therefore mixed. Raw materials, energy, freight and manufacturing are important, especially in ingredients and nutrition. But the share of value added by R&D, sensory science, regulatory support, application labs and customer-embedded design work is high enough that scale improves economics over time. That is why Perfumery & Beauty can defend a margin above 21% even when FX hits reported sales, and why TTH’s margin improved to 20.6% in 2025 despite softer second-half demand. Operating leverage here is steadier and slower than a software business's drop-through: once plants, creative centers and scientific/regulatory teams are in place, volume growth and mix improvement can lift margins meaningfully, but the company still needs continuous capex and R&D to protect relevance.

The moat is real, but it is narrower than management’s broad language implies. The strongest moat is customer stickiness rooted in formulation work and regulatory complexity. A large fine-fragrance customer or global food-and-beverage customer does not swap suppliers casually, because reformulation changes sensory outcomes, qualification files, production performance and launch timing. The second moat is technology and captive ingredient depth. dsm-firmenich describes Perfumery & Beauty as supported by an “unmatched palette of captive ingredients” and a vertically integrated supply chain; in this industry, captive molecules matter because they support differentiation in both creative performance and procurement resilience. The third moat is global scale with local application capability: these companies win business not merely by owning molecules, but by translating them into localized product wins for multinational and regional customers. The fourth moat is regulatory and scientific infrastructure, especially in HNC and food applications. These are businesses where approvals, claims, stability, quality systems and customer documentation are part of the product.

What is not a moat is the broad portfolio by itself. ANH proved that point. Being present in vitamins, feed additives and methane-reduction solutions did not automatically improve the quality of the group. In fact, the 2026 CVC deal implies that the market placed a meaningfully lower multiple on the remaining ANH activities than on the more consumer-facing businesses. That is the clearest evidence that not all exposure to “nutrition” is equal. The market pays up for formulation-heavy, customer-embedded ingredients. It does not pay the same way for businesses whose economics are more exposed to commodity cycles, vitamin pricing and farm-gate demand.

Governance looks broadly sound, though not frictionless. DSM-Firmenich AG is organized under Swiss law, listed in Amsterdam and now also on SIX. Thomas Leysen remains chairman, Dimitri de Vreeze is CEO, Patrick Firmenich is vice-chair, and the board still includes Antoine Firmenich. The shareholder structure confirms that the Firmenich family remains influential: AFM disclosures show Patrick Firmenich with 1.71% capital interest but 22.10% voting rights, and F. Guntern-Burrus with 0.87% capital interest and the same 22.10% voting-rights disclosure; Norges Bank held 5.03% and BlackRock 4.53% capital interest in the cited filings. The family stake is therefore not a footnote. It remains part of the governing equilibrium of the merged company. That is not necessarily bad. It does mean outside shareholders should assume that long-term control and culture still carry a family imprint even inside a public-company framework.

The balance sheet is stronger than the bear case often assumes. The group carries A3 from Moody’s and A- from S&P, both with stable outlooks, and in 2024 arranged a new €1.8 billion revolving credit facility with no financial covenants or material adverse change clauses. That is useful not because dsm-firmenich is highly levered, but because it gives the company room to complete the ANH separation, support buybacks, and keep investing without turning every portfolio step into a refinancing question.

Industry structure is favorable. Flavors and fragrances remain an oligopoly with a handful of global-scale players that can serve multinational customers across geographies and categories. Customer concentration at the end-market level is high, but supplier substitution is limited by formulation complexity, service capability and compliance. Profit pools are highest where ingredients are both performance-critical and small in their percentage of end-product cost: fine fragrance, active beauty, premium taste systems, infant nutrition ingredients and specialized health solutions. Profit pools are weaker where input prices dominate, end-demand is more cyclical, or customers treat ingredients as near-commodities. That is exactly why dsm-firmenich’s consumer pivot should increase the quality of its earnings even if it trims revenue scale on paper.

The cycle profile is mixed. Perfumery and many food ingredients are relatively defensive by industrial standards, but they are not immune to destocking and consumer caution. The recent pattern shows this clearly: P&B remained strong while TTH and HNC softened when customer behavior turned more cautious. ANH added a much harder inventory and commodity cycle than the rest of the group; removing it should lower volatility. The main cyclical exposures now are consumer demand, inventory normalization, FX, freight and raw-material inflation, not capital spending or a classic commodity supercycle.

Regulatory and legal risk is part of the background. In March 2026 Reuters reported that India’s antitrust watchdog was investigating Givaudan, Firmenich and IFF over alleged anti-poaching arrangements, while earlier U.S. litigation over fragrance-ingredient price fixing had survived dismissal motions and still implicated several leading industry players. These matters are not specific enough in the evidence set to quantify for dsm-firmenich, but they are a reminder that oligopolies with sticky customers and concentrated shares can attract scrutiny.

Horizontal competitor analysis

The best way to understand dsm-firmenich is to place it between three very different peers. Givaudan is what purity looks like when the flavor-and-fragrance model is allowed to mature without much distraction. Customers choose Givaudan for reliability, creative excellence, scale, and an unusually consistent ability to price and pass through costs while preserving margin. Symrise is the closest operating reference because it mixes flavors, fragrances, cosmetic ingredients and functional ingredients with a more balanced capital-allocation discipline and a distinctly German execution culture. IFF is the cautionary peer: it has immense scale and good assets, but struggled after becoming too broad and too leveraged, and it is now simplifying through disposals of its own. dsm-firmenich sits between Symrise and Givaudan in business quality, and well ahead of IFF in strategic clarity, though not yet in clean premium status.

What customers genuinely buy from dsm-firmenich is slightly different from what they buy from Givaudan. Givaudan is the gold standard in a narrower lane. dsm-firmenich tries to sell a broader co-creation package across taste, texture, health, beauty and fragrance, which gives it more touchpoints but also more execution burden. That breadth is an advantage when a customer wants a single partner on multiple formulation problems. It is a disadvantage when investors want a very clean, easily modeled premium story. Symrise has long benefited from this middle position: broad enough to capture adjacent value, focused enough to keep the equity story intelligible. dsm-firmenich is trying to move into that zone after shedding ANH.

The current financial comparison supports that reading.

† Givaudan CHF figures and IFF USD figures translated into EUR at ECB reference rates for 2026-07-03 of EUR 1 = CHF 0.9190 and EUR 1 = USD 1.1448. dsm-firmenich market cap is calculated from the 2026-07-03 close and 253,626,947 issued shares; other market caps use Reuters/LSEG snippets.

The table says three useful things. First, dsm-firmenich is already large enough that lack of scale is not the issue. The reason it does not get a Givaudan multiple is margin quality and consistency, not size. Second, the stock is not plainly cheap against Symrise; the two companies sit in a similar EV/EBITDA neighborhood, which means investors are already giving dsm-firmenich some credit for its cleaner future shape. Third, the discount to Givaudan is real and deserved, but it is not fixed forever. If dsm-firmenich can prove that P&B strength is durable, TTH can grow without heavy price support, and HNC can stop wobbling, the gap can narrow. If those things fail, the stock may drift toward the more skeptical end of Symrise/IFF-style valuation instead.

Ecologically, dsm-firmenich is a leader in transition. It occupies the market gap between the pure fragrance/flavor houses and broader health-and-nutrition ingredients groups, short of Givaudan's category-king premium perception but well past a mere follower position. That niche becomes stronger if customers increasingly want integrated reformulation help across taste, texture, wellness and beauty. It becomes weaker if the market reverts to rewarding narrow specialists and if management cannot make the broader proposition translate into better margins.

Current fundamentals and valuation analysis

The last four reported quarters show a business that improved in 2025, then entered 2026 with mixed but encouraging momentum. Full-year 2025 continuing operations delivered 3% organic sales growth, led by 3% in P&B, 4% in TTH and 3% in HNC, while adjusted EBITDA rose to €1.772 billion and core adjusted ROCE improved to 11.1%. Q4 2025 was softer, especially in TTH and HNC, because cautious customer behavior and destocking picked up in the second half. Q1 2026 then showed 4% like-for-like growth for continuing operations, fully volume-driven, with P&B up 8%, TTH reported at 2% LFL or 3% volume-based before the Bovaer year-on-year effect, and HNC up 4%. Reported sales still fell 3% because of FX and M&A effects, and group margin slipped to 19.1% from 19.7%, partly because of freight and energy costs linked to the Middle East conflict.

The strongest current fact is that Perfumery & Beauty is carrying the group. Fine Fragrance posted strong double-digit LFL growth in Q1 2026, Consumer Fragrances grew high single digits, and P&B held a 22% adjusted EBITDA margin, basically in line with its already strong 2025 average. That is exactly the piece of evidence bulls wanted: the business with the best quality is also the one with the best momentum. The softer fact is that some of this Q1 strength came from customers advancing orders because of supply-chain uncertainty around the Middle East. That does not invalidate the demand. It does caution against annualizing the quarter too aggressively.

Management’s 2026 outlook remains pragmatic rather than promotional. The company guided continuing operations to 2–4% like-for-like sales growth, around 20% adjusted EBITDA margin, and 11–12% cash conversion for the full year, assuming only limited impact from the Middle East conflict in the second half. That is the language of a company still trying to anchor cash and margin discipline while waiting for a more normal demand backdrop, not one already declaring peak potential.

What the market is trading right now is therefore a blend of real fundamentals and narrative. The real fundamentals are these: cost synergies are delivered, revenue synergies are arriving, ANH is on the way out, P&B is strong, cash generation is decent, the balance sheet is healthy, and management is buying stock back at scale. The narrative piece is the idea that after ANH closes, the market will be willing to re-rate dsm-firmenich toward the premium end of the peer set. That could happen. It is not automatic. The fact that formal reporting still shows three continuing business units and that two of them still face soft demand means there is still execution work between story and rerating.

The bull case rests on four pieces of evidence. First, management has delivered the cost side of the synergy plan: €175 million of cost synergies are done, not merely promised. Second, the portfolio is materially better after Feed Enzymes and the ANH agreement, which should lift average quality even if sales size shrinks. Third, P&B’s Q1 2026 performance suggests the company owns a genuinely premium business with more upside than the consolidated numbers show. Fourth, the buyback converts portfolio simplification into per-share accretion, and by 2026-06-30 the program had already retired 4.36 million shares for €284.9 million, with completion still targeted by the end of Q3 2026.

The bear case also rests on real evidence. First, the ANH deal leaves only about €0.6 billion of net cash proceeds at closing and includes vendor financing plus a retained 20% stake, which is less clean than a simple monetization. Second, TTH and HNC are not yet delivering the kind of broad-based momentum that would justify a Givaudan-style premium. Third, part of Q1’s strength came from order pull-forward linked to geopolitical risk, so near-term growth may flatter the run rate. Fourth, litigation and antitrust scrutiny remain an industry issue, especially in fragrances.

Historical-valuation analysis is messy because the merger, ANH reclassification, and large impairments distort simple P/E history. EV/EBITDA and owner-earnings yield are more useful. On 2025 continuing-operations adjusted EBITDA, the stock trades around 14.0x EV/EBITDA. That sits materially below Givaudan’s rough 20.3x and close to Symrise’s 13.3x, while above IFF’s roughly 12.0x. On 2025 adjusted gross operating free cash flow of €950 million, the equity trades on an owner-earnings yield of about 4.4%. That is not distressed. It is not generous either for a business still proving its post-ANH earnings shape.

The cash-flow passthrough check is important here. For 2025 continuing operations, AGOFCF was €950 million versus core adjusted net profit of €887 million, and for 2024 it was €1,217 million versus €976 million. The short record therefore shows operating economics that convert into cash reasonably well. Because AGOFCF already subtracts capex and adjusts working capital, it is a sensible owner-earnings anchor for valuation. The reported IFRS earnings line is much less useful because of reclassification effects and non-cash impairments tied to the ANH disposal.

The valuation scenarios below use owner earnings as the primary anchor and EV/EBITDA as a cross-check. They are not investment advice.

These scenarios point to a stock that is neither obviously cheap nor obviously expensive. The current price is only modestly below my base-case estimate and above my conservative fair value point. That means the market is already paying for some normalization and some quality improvement. The expectation gap is therefore narrow: the stock does not need perfection, but it does need evidence that 2026’s consumer-focused version of dsm-firmenich really deserves to live closer to Symrise than to IFF on quality perception, and eventually closer to Givaudan on some portions of the portfolio.

On margin of safety, the answer at the current price is blunt. Against the conservative scenario, there is no margin of safety for a new buyer. Against the base scenario, the stock is still acceptable for a holder who already owns it and believes the consumer pivot will continue. That is why this report ends at Hold rather than Buy. The business is good enough to own; the price is not low enough to remove execution risk.

Risks, catalysts, synthesis and sources

The main permanent-loss risks are specific, not abstract. The first is execution risk in the post-ANH shape. If P&B remains strong but TTH and HNC stay soft, the group will still look like one excellent business and two merely decent ones. That caps the multiple. The observable indicator is segment-level LFL growth and whether TTH/HNC can sustain at least low-to-mid single-digit volume growth without sacrificing margin. The second risk is transaction-quality risk on ANH. The economic package includes 20% retained equity, a vendor loan note, and support facilities, so a clean close without later value leakage matters. The observable indicator is the final closing announcement and any update on cash proceeds, transition financing or earn-out terms. The third is cost inflation and geopolitical disruption. Q1 already showed freight and energy pressure from the Middle East conflict, and management explicitly built its outlook on the assumption of only limited second-half impact. A wider disruption would hit margin first and narrative second. The fourth is legal and regulatory scrutiny in fragrances; the India anti-poaching investigation and ongoing antitrust litigation across the industry show that these oligopolies are politically visible.

Positive catalysts are easier to identify than to time. The biggest would be a formally completed ANH closing with no deterioration in proceeds and no ugly transition financing surprises. The second would be evidence that Q1’s volume-led growth was not merely order pull-forward, especially if TTH improves from soft conditions and HNC gains more traction in biomedical and early-life nutrition. The third would be continued buyback execution at disciplined prices; by 2026-06-30 the company had spent €284.9 million under the March program and still intended to finish the capital-reduction leg by end-Q3 2026. The fourth would be further proof that revenue synergies can keep converting into EBITDA now that cost synergies are largely harvested.

A compact tracking dashboard is enough.

The point of this dashboard is to distinguish between a stock that is merely waiting for the ANH close and a stock whose core businesses are actually improving. The next hard checkpoint is the publication of H1 2026 results on 2026-07-30, according to the company’s financial calendar.

The cross-synthesis is straightforward. Vertically, dsm-firmenich has proven that it can do large portfolio surgery. DSM transformed itself over decades from mining to chemicals to nutrition; Firmenich remained private for more than a century while building a globally relevant fragrance and taste house; the merged company has already shown willingness to cut away lower-quality volume to protect future quality. That is a real capability. What it has not yet proven is that the broader post-merger platform deserves to be valued as a premium compounder rather than as a good but still-transitioning ingredients group. Horizontally, its strongest advantage over peers is breadth with real scientific depth. Its weakest point is that breadth still asks for more managerial proof than a narrower pure-play requires.

Bull reasons, stated plainly. One, cost synergy delivery is no longer hypothetical because €175 million has already been delivered and completed. Two, the company is exiting the business that most obscured the quality of the remaining group. Three, Perfumery & Beauty is performing like a premium franchise, with 8% LFL growth in Q1 2026 and a 22% margin. Four, cash conversion is solid enough that capital returns are credible rather than decorative.

Bear reasons, equally plainly. One, the ANH exit is strategically right but financially less clean than hoped, because it includes retained equity and vendor support rather than a pure-cash monetization. Two, TTH and HNC still have not produced the broad-based acceleration that would fully justify a rerating. Three, Q1 2026 contained some order advancement tied to geopolitical supply-chain worries. Four, the company still faces industry legal and antitrust overhangs in fragrances. Five, at €85 the stock does not offer a conservative margin of safety for new capital.

Pre-mortem. The first script for being badly wrong is a “false dawn in mix quality” script. During 2026 and 2027, fine fragrance cools after the order pull-forward, TTH stays stuck near zero-to-low-single-digit growth, and HNC remains weak in North American consumer health. Group margin fails to move beyond 20%, revenue synergies flatten, and the market stops believing in a premium rerating. A stock on roughly 14x EV/EBITDA could easily fall to 10x-11x if that happens, especially if owner earnings stagnate. A 40%–50% drawdown would not be extreme in that scenario. The second script is an “ANH cleanup turns messy” script. Closing slips, transition financing grows, retained-stake monetization looks uncertain, and management has to defend why the consumer pivot generated less cash than investors expected. That would hit both the balance-sheet narrative and capital-allocation credibility at the same time.

My final conclusion is that dsm-firmenich is a better business today than the market thought a year ago, but not yet a cheap one. The company has done the hard strategic work: it merged two long-lived franchises, delivered the cost side of synergies, improved cash discipline, and is shedding the lowest-quality, highest-volatility business. The best asset in the portfolio, Perfumery & Beauty, is growing well enough to justify optimism. The thing that still holds me back from a more aggressive stance is the unresolved question of how much of the rest of the group can rise with it, and whether the ANH exit will prove financially elegant rather than merely strategically correct.

At the current price, the stock looks like a reasonable hold for investors who already own the transition, and a patience name for those who do not. I would rather buy it on a larger discount, after the ANH closing is visible in primary disclosures and after one or two more quarters show that TTH and HNC can participate in the improvement instead of watching P&B do all the heavy lifting. What would change my mind positively is a clean ANH close, sustained volume growth without pull-forward effects, and evidence that owner earnings can move toward the upper end of the scenario range. What would change my mind negatively is margin slippage below 19%, stalled cash conversion, or any sign that the retained economics in ANH drag on longer than investors expect.

【Company-profile scores】

• Fundamental quality: medium
• Growth: medium
• Moat: medium
• Financial soundness: strong
• Management credibility: medium
• Valuation attractiveness: low
• Risk level: medium
• Suitable investor type: long-term growth

【Investment rating】

• Rating: Hold
• One-line thesis: The portfolio is getting better faster than the old bear case assumed, but €85 already prices a fair share of that cleanup.
• 【Ideal Buy Price】64–70 EUR Basis: at least a 20% discount to the conservative fair-value point of about €82 per share.
• Acceptable hold price: 80–108 EUR
• Clearly overvalued price: 121 EUR and above
• Current-price classification: acceptable hold
• Whether to wait for a better price: yes; I would prefer to buy below €70, ideally after a clean ANH closing and with evidence that TTH/HNC are stabilizing. The opportunity cost of waiting is missing modest rerating upside if execution keeps improving.
• Target holding horizon: 3–5 years
• Expected annualized return: conservative about 2%–4%; base about 7%–9%; optimistic about 12%–14%
• Max-loss risk: about 45% to 50% in a false-dawn scenario where margin stalls near 19%–20% and the market de-rates the shares toward low-teens EV/EBITDA
• Reassessment-trigger signals: if group adjusted EBITDA margin falls below 19% for two consecutive quarters; if P&B LFL growth drops below 3% for two quarters; if cash conversion falls below 10%; if the ANH closing terms deteriorate materially; if legal or antitrust actions escalate into financial penalties or major conduct remedies.

【Valuation Range】

• current: 85.00 (close as of 2026-07-03)
• bear (conservative · ideal buy zone): [64, 70]
• base (fair · acceptable hold zone): [80, 108]
• bull (optimistic · above the clearly-overvalued line): [121, 135]

Open questions and limitations. Public evidence through 2026-07-04 is enough to judge the direction of travel, but not enough to settle every detail. The biggest open item is deal-completion status and final economics on ANH; in the evidence reviewed here, the agreement is clear but a closing announcement was not found. The second open item is the eventual reporting architecture after ANH leaves: the latest primary materials still show three continuing business units, not a formally disclosed two-pillar segment basis. The third is cultural integration: synergy data support operational progress, but public disclosure is naturally thinner on whether the legacy DSM and Firmenich ways of working have fused into a durable advantage.

Sources used for the core judgment were the company’s 2025 full-year report and integrated annual report, the March 2026 Investor Event materials, the May 2026 Q1 trading update, the February and June 2026 ANH and buyback disclosures, shareholder-register filings with the Dutch AFM, Reuters/LSEG market-data snippets for current market values and event reactions, ECB reference rates for currency conversion, and official peer disclosures from Givaudan, Symrise and IFF.

Other tickers mentioned

• GIVN.SWX: closest premium fragrance-and-flavor peer and the clearest benchmark for a full-quality multiple
• SY1G.DE: the closest balanced flavors-fragrances-functional-ingredients comp for operating and valuation comparison
• IFF.US: a useful broad-portfolio peer and a warning that scale without focus can keep valuation compressed
• KRZ.IR: a food-ingredients reference point on taste and nutrition breadth, though less directly comparable in fragrances

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.